<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00060450</url>
  </required_header>
  <id_info>
    <org_study_id>MACIN1</org_study_id>
    <nct_id>NCT00060450</nct_id>
  </id_info>
  <brief_title>Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation</brief_title>
  <official_title>Inhaled Nitric Oxide in Prevention/Treatment of Ischemia-Reperfusion Lung Injury Related to Lung Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mallinckrodt</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mallinckrodt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of inhaled nitric oxide on both
      short-term physiology as well as on the development of ischemia-reperfusion lung injury
      (IRLI) in the immediate post transplant period. The specific hypothesis is that inhaled NO
      post lung transplantation will improve gas exchange/hemodynamic and thus reduce the
      development of post transplant IRLI.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective is to determine the role of inhaled NO in the prevention/treatment of IRLI in
      lung transplant patients. The plan is to accomplish this objective in 2 phases:

      Phase 1 - patients immediately post transplant will have a variety of physiologic
      measurements performed while breathing 0, 10, and 20 ppm inhaled NO. For the next 24 hours
      they will be kept on a mixture providing the best oxygen delivery and pulmonary artery
      pressure. Our specific aims in this phase are to characterize physiologic responses to
      inhaled NO and determine the incidence of IRLI in these patients over 24 hours.

      Phase 2 - patients immediately post transplant will be randomized to either INO or placebo
      gas and followed for 24 hours. Our specific aim in this phase is to compare the rate of
      development of IRLI in the two groups.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow Enrollment
  </why_stopped>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">September 2006</completion_date>
  <primary_completion_date type="Actual">September 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>arterial and mixed venous blood gases</measure>
    <time_frame>first 4 hours post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>pulmonary vascular pressures</measure>
    <time_frame>first 4 hours post transplant</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cardiac output</measure>
    <time_frame>first 4 hours post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systemic hemodynamics</measure>
    <time_frame>first 4 hours post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NO2 and NO concentrations</measure>
    <time_frame>duration of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Ischemia-Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Inhaled Nitric Oxide</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gas</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nitric oxide for inhalation</intervention_name>
    <description>Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant</description>
    <arm_group_label>1</arm_group_label>
    <other_name>INOmaxÂ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Patients undergoing lung transplantation

        Exclusion criteria:

          -  Participation in other experimental protocols
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neil MacIntyre, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 6, 2003</study_first_submitted>
  <study_first_submitted_qc>May 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2003</study_first_posted>
  <last_update_submitted>September 8, 2016</last_update_submitted>
  <last_update_submitted_qc>September 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemia-reperfusion lung injury</keyword>
  <keyword>IRLI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

